{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:01:44Z","timestamp":1770188504645,"version":"3.49.0"},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["GH5342, OPP1201530, OPP1190749, OPP12015, INV-021433"],"award-info":[{"award-number":["GH5342, OPP1201530, OPP1190749, OPP12015, INV-021433"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007338","name":"Foundation for Barnes-Jewish Hospital","doi-asserted-by":"publisher","award":["4930"],"award-info":[{"award-number":["4930"]}],"id":[{"id":"10.13039\/100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project conducts clinical and translational research to accelerate the global elimination of lymphatic filariasis (LF) and onchocerciasis (river blindness). Research needs were identified during several meetings of experts and helped study design. Over the last 15 years the project has conducted mass drug administration (MDA) studies and clinical trials with outstanding research teams in 11 countries that have led to many important discoveries. For example, DOLF studies showed that annual MDA was as effective as semiannual MDA for LF elimination and that semiannual MDA with albendazole alone can eliminate LF in areas where ivermectin cannot be safely used. Multiple studies showed that a single dose of the triple-drug combination ivermectin plus diethylcarbamazine and albendazole (IDA) was well tolerated and more effective than previously recommended treatments for LF. Results of these studies led the World Health Organization (WHO) to endorse IDA for LF elimination programs in countries without coendemic onchocerciasis or loiasis. More recently, we have shown that single-dose treatment with moxidectin plus albendazole is superior to the ivermectin plus albendazole regimen currently recommended for LF elimination in Africa. Safety and efficacy studies of combination treatments for onchocerciasis have shown that IDA is more effective against adult\n                    <jats:italic>Onchocerca volvulus<\/jats:italic>\n                    worms than ivermectin plus albendazole, although the effect was modest. We are currently testing the macrofilaricidal efficacy of other drug combinations and treatment schedules. DOLF researchers have also conducted important studies that are not clinical trials. For example, we discovered that some people with high\n                    <jats:italic>Loa loa<\/jats:italic>\n                    microfilaria (Mf, first-stage larvae) densities have cross-reactive filarial antigen tests. DOLF has also addressed the issue of MDA compliance, because improved treatments cannot be effective if people do not swallow the tablets. We highlight here some of DOLF\u2019s important discoveries that support the control and elimination of neglected tropical diseases caused by helminths.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0013953","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:27:39Z","timestamp":1770143259000},"page":"e0013953","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project: Accomplishments and ongoing research"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-3417","authenticated-orcid":true,"given":"Peter U.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Budge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the DOLF Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"10","key":"pntd.0013953.ref001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000317","article-title":"The global programme to eliminate lymphatic filariasis: health impact after 8 years","volume":"2","author":"EA Ottesen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0013953.ref002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.2008.79.480","article-title":"Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs","volume":"79","author":"D Kyelem","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0013953.ref003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1756-3305-4-205","article-title":"Onchocerciasis in the Americas: from arrival to (near) elimination","volume":"4","author":"K Gustavsen","year":"2011","journal-title":"Parasit Vectors"},{"issue":"7","key":"pntd.0013953.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000497","article-title":"Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal","volume":"3","author":"L Diawara","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013953.ref005","article-title":"Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(\u00ae)) monotherapy","author":"EW Cupp","year":"2011","journal-title":"Acta Trop"},{"issue":"9","key":"pntd.0013953.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001825","article-title":"Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal","volume":"6","author":"MO Traore","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0013953.ref007","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bull World Health Organ"},{"key":"pntd.0013953.ref008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1179\/136485908X337436","article-title":"The African Programme for Onchocerciasis Control (APOC)","author":"U Amazigo","year":"2008","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0013953.ref009","volume-title":"Global programme to eliminate lymphatic filariasis: progress report 2000-2009 and strategic plan 2010-2020. Contract No.: WHO\/HTM\/NTD\/PCT\/2010.6","year":"2010"},{"issue":"1","key":"pntd.0013953.ref010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40249-016-0147-4","article-title":"The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014)","volume":"5","author":"HC Turner","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"pntd.0013953.ref011","unstructured":"WHO\/APOC. Moving from control to elimination where feasible: forecasting and categorization of APOC projects. 2010 02 July 2010. Report No."},{"issue":"11","key":"pntd.0013953.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002447","article-title":"A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis","volume":"7","author":"A Krentel","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013953.ref013","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12879-022-07811-7","article-title":"Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin","volume":"22","author":"UF Ekpo","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"2","key":"pntd.0013953.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009091","article-title":"Progress towards onchocerciasis elimination in C\u00f4te d\u2019Ivoire: a geospatial modelling study","volume":"15","author":"OA Eneanya","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0013953.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006897","article-title":"Update on the current status of onchocerciasis in C\u00f4te d\u2019Ivoire following 40 years of intervention: progress and challenges","volume":"12","author":"BG Koudou","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013953.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/inthealth\/ihx039","article-title":"Progress toward elimination of onchocerciasis in the Americas","volume":"10","author":"M Sauerbrey","year":"2018","journal-title":"Int Health"},{"issue":"3","key":"pntd.0013953.ref017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4269\/ajtmh.20-0195","article-title":"Elimination of simulium neavei-transmitted onchocerciasis in Wambabya-Rwamarongo focus of Western Uganda","volume":"103","author":"MN Katabarwa","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0013953.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001984","article-title":"Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis","volume":"7","author":"WA Stolk","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0013953.ref019","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.21-0768","article-title":"Impact of annual versus semiannual mass drug administration with ivermectin and albendazole on helminth infections in southeastern Liberia","volume":"106","author":"OA Eneanya","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0013953.ref020","doi-asserted-by":"crossref","first-page":"106437","DOI":"10.1016\/j.actatropica.2022.106437","article-title":"Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia","volume":"231","author":"OA Eneanya","year":"2022","journal-title":"Acta Trop"},{"issue":"2","key":"pntd.0013953.ref021","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4269\/ajtmh.18-0570","article-title":"Comparison of the impact of annual and semiannual mass drug administration on lymphatic filariasis prevalence in Flores Island, Indonesia","volume":"100","author":"T Supali","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"pntd.0013953.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012979","article-title":"Semi-annual and annual mass drug administration of diethylcarbamazine and albendazole are equally effective regimens for eliminating lymphatic filariasis in Papua New Guinea","volume":"19","author":"MC Payne","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013953.ref023","year":"2017"},{"issue":"9070","key":"pntd.0013953.ref024","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet"},{"key":"pntd.0013953.ref025","article-title":"Albendazole: a review of anthelmintic efficacy and safety in humans","author":"J Horton","year":"2000","journal-title":"Parasitology"},{"issue":"12","key":"pntd.0013953.ref026","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/cid\/ciab194","article-title":"Semiannual treatment of albendazole alone is efficacious for treatment of lymphatic filariasis: a randomized open-label trial in Cote d\u2019Ivoire","volume":"74","author":"AF Ouattara","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0013953.ref027","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4269\/ajtmh.14-0661","article-title":"The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo","volume":"92","author":"SDS Pion","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pntd.0013953.ref028","article-title":"The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Democratic Republic of the Congo","volume":"14","author":"SDS Pion","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0013953.ref029","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"SDS Pion","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pntd.0013953.ref030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4269\/ajtmh.21-0731","article-title":"Impact of semi-annual albendazole on lymphatic filariasis and soil-transmitted helminth infection: parasitological assessment after 14 rounds of community treatment","volume":"106","author":"SDS Pion","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0013953.ref031","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1232","article-title":"Results from 2 cohort studies in central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence","volume":"73","author":"JT Campillo","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0013953.ref032","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13071-021-04814-2","article-title":"A strong effect of individual compliance with mass drug administration for lymphatic filariasis on sustained clearance of soil-transmitted helminth infections","volume":"14","author":"JT Campillo","year":"2021","journal-title":"Parasit Vectors"},{"issue":"9","key":"pntd.0013953.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008642","article-title":"Impact of annual and semi-annual mass drug administration for lymphatic filariasis and onchocerciasis on hookworm infection in C\u00f4te d\u2019Ivoire","volume":"14","author":"A Loukouri","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013953.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012851","article-title":"Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea","volume":"19","author":"JA Tobon Ramos","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013953.ref035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pntd.0013953.ref036","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in C\u00f4te d\u2019Ivoire: an open-label randomized controlled trial","volume":"71","author":"CM Bjerum","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"19","key":"pntd.0013953.ref037","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"pntd.0013953.ref038","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-dose triple-drug therapy for wuchereria bancrofti\u20145-year follow-up","volume":"382","author":"CL King","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"pntd.0013953.ref039","article-title":"Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in C\u00f4te d\u2019Ivoire","volume":"13","author":"C Edi","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013953.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"T Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013953.ref041","first-page":"111","article-title":"Surveillance and selective treatment of brugia malayi filariasis eleven years after stopping mass drug administration in Belitung District, Indonesia","volume":"110","year":"2023","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0013953.ref042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"PU Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0013953.ref043","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"MA Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pntd.0013953.ref044","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med"},{"key":"pntd.0013953.ref045","first-page":"13","article-title":"Lessons from large-scale tolerability and acceptability studies of triple drug mass drug administration performed to support policy change and accelerate elimination of lymphatic filariasis","volume":"106","author":"GJ Weil","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0013953.ref046","article-title":"A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: from conception to delivery","volume":"13","author":"GJ Weil","year":"2020","journal-title":"Int Health"},{"issue":"3","key":"pntd.0013953.ref047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"A Krentel","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"40","key":"pntd.0013953.ref048","first-page":"439","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2024","author":"WHO","year":"2025","journal-title":"Weekly epidemiological record"},{"issue":"1887","key":"pntd.0013953.ref049","doi-asserted-by":"crossref","first-page":"20220276","DOI":"10.1098\/rstb.2022.0276","article-title":"Modernizing the design and analysis of prevalence surveys for neglected tropical diseases","volume":"378","author":"PJ Diggle","year":"2023","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"pntd.0013953.ref050","doi-asserted-by":"crossref","DOI":"10.1093\/inthealth\/ihaa084","article-title":"Evolution of the monitoring and evaluation strategies to support the World Health Organization\u2019s Global Programme to Eliminate Lymphatic Filariasis","volume":"13","author":"PJ Lammie","year":"2020","journal-title":"Int Health"},{"issue":"1","key":"pntd.0013953.ref051","article-title":"Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea","volume":"19","author":"K Bun","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0013953.ref052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013593","article-title":"Brugia malayi and other filarial parasite species in animals in areas endemic for lymphatic filariasis in Belitung District, Indonesia","volume":"19","author":"I Diekmann","year":"2025","journal-title":"PLoS Negl Trop Dis"},{"issue":"10154","key":"pntd.0013953.ref053","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"pntd.0013953.ref054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011633","article-title":"Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in C\u00f4te d\u2019Ivoire: a randomized controlled superiority study","volume":"17","author":"CM Bjerum","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0013953.ref055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011567","article-title":"Pharmacokinetics of moxidectin combined with albendazole or albendazole plus diethylcarbamazine for bancroftian filariasis","volume":"17","author":"YS Chhonker","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0013953.ref056","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1473-3099(25)00111-2","article-title":"Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial","volume":"25","author":"GB Koudou","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0013953.ref057","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.mcpro.2022.100454","article-title":"Direct proteomic detection and prioritization of 19 onchocerciasis biomarker candidates in humans","volume":"22","author":"BA Rosa","year":"2023","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"pntd.0013953.ref058","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciz889","article-title":"Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial","volume":"71","author":"L Batsa Debrah","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0013953.ref059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011365","article-title":"A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis","volume":"17","author":"NO Opoku","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013953.ref060","doi-asserted-by":"crossref","first-page":"1099926","DOI":"10.3389\/fmed.2023.1099926","article-title":"Histopathological evaluation of Onchocerca volvulus nodules by microscopy and by digital image analysis for the study of macrofilaricidal drug efficacy","volume":"10","author":"K Fischer","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pntd.0013953.ref061","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4269\/ajtmh.21-0859","article-title":"A reevaluation of the tolerability and effects of single-dose ivermectin treatment on Onchocerca volvulus microfilariae in the skin and eyes in Eastern Ghana","volume":"106","author":"NO Opoku","year":"2021","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"pntd.0013953.ref062","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.pt.2024.07.005","article-title":"The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis","volume":"40","author":"F Risch","year":"2024","journal-title":"Trends Parasitol"},{"issue":"10","key":"pntd.0013953.ref063","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0169-4758(97)01130-7","article-title":"The ICT Filariasis Test: a rapid-format antigen test for diagnosis of bancroftian filariasis","volume":"13","author":"GJ Weil","year":"1997","journal-title":"Parasitol Today"},{"issue":"6","key":"pntd.0013953.ref064","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4269\/ajtmh.14-0358","article-title":"Filarial antigenemia and Loa loa night blood microfilaremia in an area without bancroftian filariasis in the Democratic Republic of Congo","volume":"91","author":"DK Bakajika","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"pntd.0013953.ref065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006963","article-title":"Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis","volume":"12","author":"MI Hertz","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013953.ref066","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.13-0089","article-title":"Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood","volume":"89","author":"GJ Weil","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"pntd.0013953.ref067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005703","article-title":"A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa","volume":"11","author":"CB Chesnais","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013953.ref068","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13071-015-0979-y","article-title":"A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration","volume":"8","author":"TC Yahathugoda","year":"2015","journal-title":"Parasit Vectors"},{"issue":"5","key":"pntd.0013953.ref069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010407","article-title":"Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections","volume":"16","author":"SE Greene","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0013953.ref070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011364","article-title":"IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis","volume":"17","author":"SE Greene","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0013953.ref071","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.pt.2025.08.006","article-title":"The last mile in onchocerciasis elimination: diagnostic challenges","volume":"41","author":"C Lubbers","year":"2025","journal-title":"Trends Parasitol"},{"issue":"11","key":"pntd.0013953.ref072","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.pt.2015.06.007","article-title":"Diagnostic tools for onchocerciasis elimination programs","volume":"31","author":"J Vlaminck","year":"2015","journal-title":"Trends Parasitol"},{"key":"pntd.0013953.ref073","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.actatropica.2015.03.019","article-title":"Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes","volume":"146","author":"MM Lloyd","year":"2015","journal-title":"Acta Trop"},{"issue":"12","key":"pntd.0013953.ref074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011815","article-title":"Optimized strategy for real-time qPCR detection of Onchocerca volvulus DNA in pooled Simulium sp. blackfly vectors","volume":"17","author":"M Doherty","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013953.ref075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4269\/ajtmh.18-0169","article-title":"Comprehensive assessment of a hotspot with persistent bancroftian filariasis in coastal Sri Lanka","volume":"99","author":"RU Rao","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"pntd.0013953.ref076","article-title":"Programmatic use of molecular xenomonitoring at the level of evaluation units to assess persistence of lymphatic filariasis in Sri Lanka","volume":"10","author":"RU Rao","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0013953.ref077","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3201\/eid2408.180184","article-title":"Capillaria ova and diagnosis of Trichuris trichiura infection in humans by Kato-Katz smear, Liberia","volume":"24","author":"K Fischer","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pntd.0013953.ref078","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40168-018-0416-5","article-title":"Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia","volume":"6","author":"BA Rosa","year":"2018","journal-title":"Microbiome"},{"key":"pntd.0013953.ref079","doi-asserted-by":"crossref","first-page":"105188","DOI":"10.1016\/j.ebiom.2024.105188","article-title":"Distinguishing recrudescence from reinfection in lymphatic filariasis","volume":"105","author":"Y-J Choi","year":"2024","journal-title":"EBioMedicine"},{"issue":"12","key":"pntd.0013953.ref080","article-title":"Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation","volume":"7","author":"BK Chu","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0013953.ref081","article-title":"The changing neglected tropical disease landscape in Africa: implications for policy, practice, and strengthening health systems","volume":"3","author":"P Downs","year":"2025","journal-title":"Health Aff Sch"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:27:49Z","timestamp":1770143269000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013953"}},"subtitle":[],"editor":[{"given":"Georgios","family":"Pappas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013953","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}